spirogermanium

Spirogermanium is an investigational organogermanium compound belonging to the azaspirane class, primarily studied for its potential as an antineoplastic and immunomodulatory agent. Chemically, it features a unique spiro-linked ring system containing a germanium atom. Its mechanism of action is thought to involve the inhibition of DNA and protein synthesis, although it also demonstrates the ability to induce suppressor cell activity and modulate macrophage function by inhibiting superoxide production. Clinical development reached Phase II for several indications, including breast cancer, lung cancer, and lymphomas. However, its clinical utility was significantly limited by dose-dependent neurotoxicity (such as dizziness, lethargy, and seizures) and a lack of robust efficacy in heavily pretreated patients, leading to the discontinuation of its development for most oncological indications.

Other names

8,8-diethyl-N,N-dimethyl-2-aza-8-germaspiro[4.5]decane-2-propanamine2-aza-8-germanspiro[4,5]decane-2-propamine-8,8-diethyl-N,N-dimethyl dichlorideSg